No Data
Hims & Hers Health Expands Board With New Appointment
Citi Maintains Hims & Hers Health(HIMS.US) With Hold Rating, Raises Target Price to $24
Hims & Hers Health Options Spot-On: On November 21st, 99,200 Contracts Were Traded, With 627.89K Open Interest
Express News | Shares Of Hims & Hers Health See Volume; Traders Circulate Court Filing Regarding Shortage Of Lilly's Tirzepatide Shortage, Parties Agree To Maintain Stay As Ordered By Court In October 2024, With Joint Status Report Due By December 19, 2024, Or...
Hims & Hers Closes up 10% as Lilly Tirzepatide Compounding Dispute Resolution Delayed
Hold Rating on Hims & Hers Health Amidst Regulatory Uncertainty and Market Risks
No Data
No Data
Hehehe
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}